We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prolonged Cell Division Arrest Prevents Development of Cancers Caused by Epstein-Barr Virus

By LabMedica International staff writers
Posted on 02 Feb 2016
A mechanism has been identified that helps explain why despite most people having been infected with Epstein-Barr virus (EBV), very few develop the lymphomas and other cancers the virus can cause.

EBV was the first human tumor virus discovered. More...
Although nearly all adults are infected with EBV, very few go on to develop disease, for reasons that are only now beginning to be understood.

Infection with EBV induces a period of very rapid cell division, which requires an increased supply of metabolites, such as nucleotides, amino acids, and lipids. Investigators at Duke University (Durham, NC, USA) found that EBV-infected cells that were unable to meet this increased metabolic demand were forced to stop proliferating and underwent a permanent growth arrest called senescence.

They reported in the January 22, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that arrested cells had a reduced level of mitochondrial respiration and a decrease in the expression of genes involved in the TCA (Kreb's) cycle and oxidative phosphorylation. Furthermore, the growth arrest in early infected cells could be rescued by supplementing the TCA cycle. Arrested cells were characterized by an increase in the expression of p53 pathway gene targets, including sestrins. Increased sestrin expression led to activation of AMPK (5' AMP-activated protein kinase), a reduction in mTOR (mammalian target of rapamycin) signaling, and, consequently, elevated autophagy that was important for cell survival.

In assessing the metabolic changes from early infection to long-term outgrowth, the investigators found concomitant increases in glucose import and surface glucose transporter 1 (GLUT1) levels, leading to elevated glycolysis, oxidative phosphorylation, and suppression of basal autophagy.

Senior author Dr. Micah Luftig, associate professor of molecular genetics and microbiology at Duke University, said, "For the most part, a healthy immune system stops Epstein-Barr virus from making much headway. In fact, many of the cancers linked to EBV are found mostly in immune-compromised patients whose ability to fight it off has been weakened. But another answer may be this newly discovered senescence trigger."

Related Links:

Duke University 



Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.